You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,778,675


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,778,675
Title:Immortalized avian cell lines and use thereof
Abstract: The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (VV-COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxviridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins.
Inventor(s): Balloul; Jean-Marc (Strasbourg, FR), Kapfer; Marina (Schiltigheim, FR), Menguy; Thierry (Gif S/Yvette, FR)
Assignee: Transgene S.A. (Illkirch, FR)
Application Number:13/775,314
Patent Claims:1. A method of making virus or protein using the immortalized avian cell line deposited at the European Collection of Cell Cultures (ECACC) under accession number 08060502 or 08060501.

2. The method of claim 1, wherein the protein is selected from the group consisting of antibodies, receptor ligands, hormones, cytokines, growth factors, cell adhesion molecules, blood clotting factors, enzymes, fragments thereof, and combinations thereof.

3. The method of claim 1, wherein the protein is selected from the group consisting of cytokines, antibodies, and hormones.

4. The method of claim 1, wherein the protein is selected from the group consisting of IL-2, rituximab, and erythropoietin (EPO).

5. A method of making a protein comprising the steps of: a) contacting the immortalized avian cell line deposited at the European Collection of Cell Cultures (ECACC) under accession number 08060502 or 08060501 with a recombinant vector comprising a nucleotide sequence encoding a protein; and b) culturing the cell line under conditions that allow the protein to be produced.

6. The method of claim 5, wherein the protein is selected from the group consisting of antibodies, receptor ligands, hormones, cytokines, growth factors, cell adhesion molecules, blood clotting factors, enzymes, fragments thereof, and combinations thereof.

7. The method of claim 5, wherein the protein is selected from the group consisting of cytokines, antibodies, and hormones.

8. The method of claim 5, wherein the protein is selected from the group consisting of IL-2, rituximab, and erythropoietin (EPO).

Details for Patent 8,778,675

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2029-05-12
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 ⤷  Try a Trial 2029-05-12
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 06/22/2017 ⤷  Try a Trial 2029-05-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.